SUPPLEMENT

Q1 2022 — Financial disclosures

Q1 2022PDF · 9 pages951 KB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2022
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q22 ........................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q21.........................4
Table 3: Sales – Current Year and Prior Year by Quarter ...............5
Table 3a: Sales – U.S. / Ex- U.S. 1Q22.............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .........................7
Table 4: Other (Income) Expense ....................................................8

-- 1 of 9 --

Sales 	15,901	$ 	10,627	$ 	50%
Costs, Expenses and Other
Cost of sales 	5,380 	3,199 	68%
Selling, general and administrative 	2,323 	2,187 	6%
Research and development 	2,576 	2,412 	7%
Restructuring costs 	53 	297 	-82%
Other (income) expense, net 	708 	(455) 	*
Income from Continuing Operations Before Taxes 	4,861 	2,987 	63%
Income Tax Provision 	554 	238
Net Income from Continuing Operations 	4,307 	2,749 	57%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	4
Net Income from Continuing Operations Attributable to Merck &
Co., Inc. 4,310 	2,745 	57%
Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests - 	434 	*
Net Income Attributable to Merck & Co., Inc. 	4,310	$ 	3,179	$ 	36%
Basic Earnings per Common Share Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.08	$ 	57%
Income from Discontinued Operations 	- 	0.17 	*
Net Income 	1.70	$ 	1.26	$ 	35%
Earnings per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.08	$ 	57%
Income from Discontinued Operations 	- 	0.17 	*
Net Income 	1.70	$ 	1.25	$ 	36%
Average Shares Outstanding 	2,528 	2,531
Average Shares Outstanding Assuming Dilution 	2,537 	2,541
Tax Rate from Continuing Operations 	11.4% 	8.0%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and
established brands businesses into a new, independent, publicly traded company named Organon & Co.
(Organon). The historical results of the businesses that were contributed to Organon in the spin-off are
excluded from sales and expenses below and reflected as discontinued operations in the company’s
Consolidated Statements of Income provided below.
1Q21
GAAP
% Change
1Q22
1

-- 2 of 9 --

Sales 	15,901	$ 	10,627	$ 	11,402	$ 	13,154	$ 	13,521	$ 	48,704	$ 	50%
Costs, Expenses and Other
Cost of sales 	5,380 	3,199 	3,104 	3,450 	3,873 	13,626 	68%
Selling, general and administrative 	2,323 	2,187 	2,281 	2,336 	2,830 	9,634 	6%
Research and development 	2,576 	2,412 	4,321 	2,445 	3,068 	12,245 	7%
Restructuring costs 	53 	297 	82 	107 	174 	661 	-82%
Other (income) expense, net 	708 	(455) 	(103) 	(450) 	(333) 	(1,341) 	*
Income from Continuing Operations Before Taxes 	4,861 	2,987 	1,717 	5,266 	3,909 	13,879 	63%
Income Tax Provision 	554 	238 	503 	695 	85 	1,521
Net Income from Continuing Operations 	4,307 	2,749 	1,214 	4,571 	3,824 	12,358 	57%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	4 	1 	4 	4 	13
Net Income from Continuing Operations Attributable to Merck &
Co., Inc.
4,310 	2,745 	1,213 	4,567 	3,820 	12,345 	57%
Income (Loss) from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
- 	434 	332 	- 	(62) 	704 	*
Net Income Attributable to Merck & Co., Inc. 	4,310	$ 	3,179	$ 	1,545	$ 	4,567	$ 	3,758	$ 	13,049	$ 	36%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.08	$ 	0.48	$ 	1.81	$ 	1.51	$ 	4.88	$ 	57%
Income (Loss) from Discontinued Operations 	- 	0.17 	0.13 	- 	(0.02) 	0.28 	*
Net Income 	1.70	$ 	1.26	$ 	0.61	$ 	1.81	$ 	1.49	$ 	5.16	$ 	35%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.08	$ 	0.48	$ 	1.80	$ 	1.51	$ 	4.86	$ 	57%
Income (Loss) from Discontinued Operations 	- 	0.17 	0.13 	- 	(0.02) 	0.28 	*
Net Income 	1.70	$ 	1.25	$ 	0.61	$ 	1.80	$ 	1.48	$ 	5.14	$ 	36%
Average Shares Outstanding 	2,528 	2,531 	2,533 	2,530 	2,527 	2,530
Average Shares Outstanding Assuming Dilution 	2,537 	2,541 	2,540 	2,536 	2,535 	2,538
Tax Rate from Continuing Operations 	11.4% 	8.0% 	29.3% 	13.2% 	2.2% 	11.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
% Change
1Q
2022
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2021
2

-- 3 of 9 --

First Quarter
Cost of sales 	5,380	$ 	680 	46 	726 	4,654	$
Selling, general and administrative 	2,323 	50 	21 	71 	2,252
Research and development 	2,576 	22 	7 	29 	2,547
Restructuring costs 	53 	- 	53 	53 	-
Other (income) expense, net 	708 	(115) 	684 	569 	139
Income from Continuing Operations Before Taxes 	4,861 	(637) 	(127) 	(684) 	(1,448) 	6,309
Income Tax Provision (Benefit) 	554 	(155) (3) (22) (3) (152) (3) (329) 	883
Net Income from Continuing Operations 	4,307 	(482) 	(105) 	(532) 	(1,119) 	5,426
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 4,310 	(482) 	(105) 	(532) 	(1,119) 	5,429
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.70	$ 	(0.19) 	(0.04) 	(0.21) 	(0.44) 	2.14	$
Tax Rate 	11.4% 	14.0%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for
or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income and a
decrease in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
(3) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal
MERCK & CO., INC.
FIRST QUARTER 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
3

-- 4 of 9 --

First Quarter
Cost of sales 	3,199	$ 	497 	27 	188 (3) 712 	2,487	$
Selling, general and administrative 	2,187 	10 	3 	13 	2,174
Research and development 	2,412 	18 	7 	25 	2,387
Restructuring costs 	297 	297 	297 	-
Other (income) expense, net 	(455) 	(28) 	(561) 	(589) 	134
Income from Continuing Operations Before Taxes 	2,987 	(497) 	(334) 	561 	(188) 	(458) 	3,445
Income Tax Provision (Benefit) 	238 	(89) (4) (41) (4) 123 (4) (249) (4) (256) 	494
Net Income from Continuing Operations 	2,749 	(408) 	(293) 	438 	61 	(202) 	2,951
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 2,745 	(408) 	(293) 	438 	61 	(202) 	2,947
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.08	$ 	(0.16) 	(0.11) 	0.17 	0.02 	(0.08) 	1.16	$
Tax Rate 	8.0% 	14.3%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-
GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income, partially offset by an increase in the
estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents a charge for the discontinuation of COVID-19 development programs.
(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also includes a $208 million net tax benefit
related to the settlement of certain federal income tax matters.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
MERCK & CO., INC.
FIRST QUARTER 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
4

-- 5 of 9 --

2022
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) $15,901 	$10,627 	$11,402 	$13,154 	$13,521 	$48,704 	50 	52
PHARMACEUTICAL 	14,107 	9,238 	9,980 	11,496 	12,039 	42,754 	53 	57
Oncology
Keytruda 	4,809 	3,899 	4,176 	4,534 	4,577 	17,186 	23 	27
Alliance Revenue – Lynparza (2) 266 	228 	248 	246 	268 	989 	17 	20
Alliance Revenue – Lenvima (2) 227 	130 	181 	188 	206 	704 	75 	77
Alliance Revenue – Reblozyl (3) 52 	17 	17 	* 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,460 	917 	1,234 	1,993 	1,528 	5,673 	59 	60
ProQuad / M-M-R II / Varivax 	470 	449 	516 	661 	509 	2,135 	5 	6
RotaTeq 	216 	158 	208 	227 	213 	807 	36 	38
Pneumovax 23 	173 	171 	152 	277 	292 	893 	1 	3
Vaqta 	36 	34 	56 	48 	41 	179 	6 	6
Hospital Acute Care
Bridion 	395 	340 	387 	369 	436 	1,532 	16 	20
Prevymis 	94 	82 	93 	96 	100 	370 	14 	20
Primaxin 	58 	65 	60 	70 	65 	259 	-10 	-11
Noxafil 	57 	67 	66 	64 	62 	259 	-14 	-11
Cancidas 	53 	57 	54 	56 	45 	212 	-8 	-7
Dificid 	52 	27 	34 	54 	60 	175 	95 	96
Invanz 	52 	57 	48 	53 	45 	202 	-7 	-4
Zerbaxa 	30 	(8) 	(1) 	(2) 	10 	(1) 	* 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 72 	74 	74 	100 	94 	342 	-3 	-3
Adempas (6) 61 	55 	74 	59 	63 	252 	11 	20
Virology
Lagevrio 	3,247 	952 	952 	* 	*
Isentress / Isentress HD 	158 	209 	192 	189 	178 	769 	-24 	-21
Neuroscience
Belsomra 	69 	79 	78 	81 	80 	318 	-14 	-8
Immunology
Simponi 	186 	214 	202 	203 	206 	825 	-13 	-6
Remicade 	61 	85 	75 	73 	67 	299 	-29 	-21
Diabetes (7)
Januvia 	779 	809 	784 	852 	878 	3,324 	-4 	-1
Janumet 	454 	486 	477 	487 	514 	1,964 	-6 	-1
Other Pharmaceutical (8) 520 	554 	512 	518 	533 	2,118 	-6 	-5
ANIMAL HEALTH 	1,482 	1,418 	1,472 	1,417 	1,261 	5,568 	4 	9
Livestock 	832 	819 	821 	864 	791 	3,295 	2 	7
Companion Animals 	650 	599 	651 	553 	470 	2,273 	9 	13
Other Revenues (9) 312 	(29) 	(50) 	241 	221 	382 	* 	*
* 200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,305 million in the first quarter of 2022 and $1,363 million, $1,330 million, $1,417 million, and $1,475 million in the
first, second, third, and fourth quarter of 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging
activities. Other Revenues in the first and third quarter of 2021 include $50 million and $135 million, respectively, related to the receipt of
milestone payments for an out-licensed product.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $2,481 million in the first quarter of 2022 and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the
first, second, third and fourth quarters of 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
2021 	1Q
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
5

-- 6 of 9 --

1Q 2022 	1Q 2021 	% Change 	1Q 2022 	1Q 2021 	% Change 	1Q 2022 	1Q 2021 	% Change
TOTAL SALES (1) $15,901 	$10,627 	50 	$7,339 	$4,790 	53 	$8,563 	$5,837 	47
PHARMACEUTICAL 	14,107 	9,238 	53 	6,773 	4,294 	58 	7,334 	4,944 	48
Oncology
Keytruda 	4,809 	3,899 	23 	2,779 	2,181 	27 	2,030 	1,718 	18
Alliance Revenue - Lynparza (2) 266 	228 	17 	141 	118 	19 	125 	110 	14
Alliance Revenue - Lenvima (2) 227 	130 	75 	156 	85 	83 	71 	44 	60
Alliance Revenue - Reblozyl (3) 52 	* 	27 	* 	25 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,460 	917 	59 	418 	313 	34 	1,042 	604 	72
ProQuad / M-M-R II / Varivax 	470 	449 	5 	371 	333 	11 	99 	117 	-15
RotaTeq 	216 	158 	36 	175 	118 	48 	41 	41 	1
Pneumovax 23 	173 	171 	1 	118 	73 	62 	55 	99 	-44
Vaqta 	36 	34 	6 	29 	25 	16 	7 	9 	-24
Hospital Acute Care
Bridion 	395 	340 	16 	195 	167 	17 	199 	173 	15
Prevymis 	94 	82 	14 	40 	35 	13 	54 	47 	15
Primaxin 	58 	65 	-10 	1 	* 	58 	65 	-10
Noxafil 	57 	67 	-14 	10 	15 	-35 	48 	52 	-9
Cancidas 	53 	57 	-8 	1 	3 	-47 	52 	55 	-6
Dificid 	52 	27 	95 	49 	25 	99 	3 	2 	49
Invanz 	52 	57 	-7 	1 	4 	-80 	52 	52 	-2
Zerbaxa 	30 	(8) 	* 	18 	(2) 	* 	12 	(6) 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 72 	74 	-3 	71 	68 	4 	1 	6 	-82
Adempas (6) 61 	55 	11 	61 	55 	11
Virology
Lagevrio 	3,247 	* 	1,523 	* 	1,723 	*
Isentress / Isentress HD 	158 	209 	-24 	61 	71 	-13 	97 	138 	-30
Neuroscience
Belsomra 	69 	79 	-14 	20 	18 	13 	48 	61 	-21
Immunology
Simponi 	186 	214 	-13 	186 	214 	-13
Remicade 	61 	85 	-29 	61 	85 	-29
Diabetes (7)
Januvia 	779 	809 	-4 	325 	348 	-7 	454 	461 	-1
Janumet 	454 	486 	-6 	63 	84 	-25 	391 	401 	-3
Other Pharmaceutical (8) 520 	554 	-6 	181 	212 	-15 	339 	341 	-1
ANIMAL HEALTH 	1,482 	1,418 	4 	473 	437 	8 	1,009 	981 	3
Livestock 	832 	819 	2 	171 	157 	9 	661 	662 	-
Companion Animals 	650 	599 	9 	302 	280 	8 	348 	319 	9
Other Revenues (9) 312 	(29) 	* 	93 	59 	57 	220 	(88) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first quarter of 2021 include $50
million related to the receipt of a milestone payment for an out-licensed product.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $2,481 million in the first quarter of 2022 and $1,809 million in the first quarter of 2021.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,305 million in the first quarter of 2022 and $1,363 million in the first quarter of 2021.
(8) Includes Pharmaceutical products not individually shown above.
Table 3a
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
FIRST QUARTER 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
6

-- 7 of 9 --

2022 	% Change
TOTAL PHARMACEUTICAL 	$14,107 	$9,238 	$9,980 	$11,496 	$12,039 	$42,754 	53
United States 	6,773 	4,294 	4,647 	5,670 	5,790 	20,401 	58
% Pharmaceutical Sales 	48.0% 	46.5% 	46.6% 	49.3% 	48.1% 	47.7%
Europe (1) 3,309 	2,276 	2,404 	2,445 	2,655 	9,780 	45
% Pharmaceutical Sales 	23.5% 	24.6% 	24.1% 	21.3% 	22.1% 	22.9%
China 	1,113 	688 	944 	1,278 	1,352 	4,262 	62
% Pharmaceutical Sales 	7.9% 	7.4% 	9.5% 	11.1% 	11.2% 	10.0%
Japan 	965 	607 	637 	614 	771 	2,629 	59
% Pharmaceutical Sales 	6.8% 	6.6% 	6.4% 	5.3% 	6.4% 	6.1%
Asia Pacific (other than China and Japan) 	786 	437 	442 	450 	488 	1,817 	80
% Pharmaceutical Sales 	5.6% 	4.7% 	4.4% 	3.9% 	4.1% 	4.2%
Eastern Europe/Middle East/Africa 	450 	357 	318 	362 	278 	1,315 	26
% Pharmaceutical Sales 	3.2% 	3.9% 	3.2% 	3.1% 	2.3% 	3.1%
Latin America 	435 	353 	379 	434 	421 	1,587 	23
% Pharmaceutical Sales 	3.1% 	3.8% 	3.8% 	3.8% 	3.5% 	3.7%
Canada 	189 	160 	157 	164 	167 	650 	18
% Pharmaceutical Sales 	1.3% 	1.7% 	1.6% 	1.4% 	1.4% 	1.5%
Other 	87 	66 	52 	79 	117 	313 	32
% Pharmaceutical Sales 	0.6% 	0.8% 	0.4% 	0.8% 	0.9% 	0.8%
1Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2021
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q22 	1Q21
Interest income 	(7)	$ 	(11)	$
Interest expense 	243 	200
Exchange losses 	39 	41
Loss (income) from investments in equity securities, net (1) 708 	(574)
Net periodic defined benefit plan cost (credit) other than service cost 	(121) 	(89)
Other, net 	(154) 	(22)
Total 	708	$ 	(455)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at
the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --